Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes, EJ Jabbour - Blood reviews, 2014 - Elsevier
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …
被引用次数：46 相关文章

[引用][C] Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes, EJ Jabbour - Blood Reviews, 2014 - cir.nii.ac.jp
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of
chronic myeloid leukemia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.

MS Mathisen, HM Kantarjian, J Cortes, EJ Jabbour - Blood Reviews, 2014 - europepmc.org
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes… - Blood …, 2014 - augusta.elsevierpure.com
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes… - Blood …, 2014 - mdanderson.elsevierpure.com
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes, EJ Jabbour - Blood Reviews, 2014 - infona.pl
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

MS Mathisen, HM Kantarjian, J Cortes… - Blood …, 2014 - pubmed.ncbi.nlm.nih.gov
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …